- £75.59bn
- £90.25bn
- £32.67bn
Brief: GSK Presents Positive Data For Jideytro In First-Line Ros1-Positive NSCLC
Brief: GSK Says Ris-Rez Reduces Risk Of Death By 54% In Relapsed Small Cell Lung Cancer In China
Jideytro positive data for ROS1-positive NSCLC
UK Stocks-Factors to watch on September 14
Brief: Gsk - Presents Positive Data To Expand Jideytro To First-Line ROS1-Positive NSCLC
GSK to shut vaccine factory in Germany, putting 641 jobs at risk (updated)
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
Brief: GSK To Stop Manufacturing At Dresden, Germany Flu Vaccine Manufacturing Site In Summer 2027
Director/PDMR Shareholding
Director/PDMR Shareholding
Brief: Gsk Announces Japan Approval Of Shingrix In A Prefilled Syringe
Japan approval of Shingrix in a prefilled syringe
Director/PDMR Shareholding
Director/PDMR Shareholding
Brief: EMA Says There Is Shortage Of Albendazole-Containing Medicines Eskazole & Zentel
Brief: GSK Prices $6.50 Bln Multi-Tranche Notes Offering, Shows SEC Filing
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
UK Stocks-Factors to watch on September 3 (updated)
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug (updated)